초록

말기소화기암을 구성하는 종양미세환경을 규명하고 이를 극복하는 차세대 표적 암용해 바이러스로써 종양친화성 바이러스를 개발하여 새로운 임상적 치료전략을 확립함.

(출처 : 보고서 요약서 3p)

Abstract ▼

Purpose& Contents
To improve the weak points of the former virus (JX-594) that recently proved its efficacy through clinical treatment and to develop “Next generation oncolytic virus” fortified by higher cancer selectivity and ocolytic activity, we generated cancer favoring oncolytic virus as a n

Purpose& Contents
To improve the weak points of the former virus (JX-594) that recently proved its efficacy through clinical treatment and to develop “Next generation oncolytic virus” fortified by higher cancer selectivity and ocolytic activity, we generated cancer favoring oncolytic virus as a new virus. With the virus, we investigated its therapeutic efficacy according to cell types or cancerous stages and its mechanism. we also inestigated immuno-inflammatory tumor microenvironment to overcome the cancer drug resistance. Thus we could therapeutic strategy for cancer by regulating cancer stem cells.

Results
□ Study 1: Development of oncolytic virus targeted for late-stage gastrointestinal cancer
1^st year: We developed the optimized technique of new cancer favoring oncolytic virus targeting gastrointestinal cancer.
2^nd year: We investigated the efficacy and the mechanism of treatment for late-staged gastrointestinal cancer (liver, stomach or colon cancer).
3^rd year: We performed preclinical study in cancer xenograft aninal model such as the efficacy, cancer selectivity, safety/toxicity and drug-resistance overcoming action.

□ Study 2: Studies on tumor microenvironment-mediated tumor resistance to targeted oncolytic virotherapy in the end phage GI cancers
1^st year: We clarified immuno-inflammatory tumor microenvironment contributing to drug resistance in GI cancer.
2^nd year: We investigated cancer stem cell regulation by immuno-inflammatory tumor microenvironment and its overcoming drug resistance by our new oncolytic virus.
3^rd year: We performed preclinial study to investigate the therarpeutic effect by regulating tumor microenvironment.

Expected Contribution
-. Accomplishment of fundamental technology aimed at cancer-cure and anti-cancer new drug market, Acquisition of intellectual property right and national competitiveness.
-. Development as new paradigm anticancer drug / Providing curing opportunities for malignant cancer patients. Relieving medical expense for national welfare and making improved life quality
-. Contribution to basic science development by studying on the efficacy of Oncolytic virus and it’s mechanism attacking malignant tumor
-. Building up academical basement maximizing the effectiveness of oncolytic virus by targeting tumor microenvironment.

(출처 : SUMMARY 5p)

목차 Contents

• 표지 ... 1
• 제출문 ... 2
• 보고서 요약서 ... 3
• 국문 요약문 ... 4
• SUMMARY ... 5
• CONTENTS ... 6
• 목차 ... 7
• 1. 연구개발과제의 개요 ... 8
• 1-1. 연구개발 목적 ... 8
• 1-2. 연구개발의 필요성 ... 8
• 2. 국내외 기술개발 현황 ... 10
• 3. 연구수행 내용 및 결과 ... 12
• 4. 목표달성도 및 관련분야 기여도 ... 25
• 4-1. 목표달성도 ... 25
• 4-2. 관련분야 기여도 ... 26
• 5. 연구결과의 활용계획 ... 26
• 6. 연구과정에서 수집한 해외과학기술정보 ... 26
• 7. 연구개발성과의 보안등급 ... 27
• 8. 연구개발과제 수행에 따른 연구실 등의 안전조치 이행실적 ... 27
• 10. 연구개발과제의 대표적 연구실적 ... 28
• 10. 참고문헌 ... 29
• 별첨 ... 30
• 끝페이지 ... 56